AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14655922 — intervention group
Group type: EXPERIMENTAL
Intervention: Grammatical reasoning (GRG) response latency
Number of subjects: 15
Study 14655922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective alertness ratings
Number of subjects: 15
Study 14655922 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest performance ratings
Number of subjects: 15
Study 14655922 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttest performance ratings
Number of subjects: 15
Study 11523747 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative education program
Number of subjects: 0
Study 11523747 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg (evening dose)
Number of subjects: 16
Study 8858270 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg (morning dose)
Number of subjects: 16
Study 8858270 — intervention group
Group type: COMPARATOR
Intervention: Control (no famotidine)
Number of subjects: 16
Study 8099363 — intervention group
Group type: COMPARATOR
Intervention: Single drug therapy for induction of remission
Number of subjects: 468
Study 8099363 — intervention group
Group type: COMPARATOR
Intervention: Single drug therapy for maintenance of remission at 6 months
Number of subjects: 468
Study 8099363 — intervention group
Group type: COMPARATOR
Intervention: Single drug therapy for maintenance of remission at 12 months
Number of subjects: 468
Study 3548009 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 4 mg
Number of subjects: 120
Study 3548009 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 2 mg
Number of subjects: 120
Study 3548009 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 80 mg
Number of subjects: 120
Study 3548009 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol (4 mg) vs Meperidine (80 mg)
Number of subjects: 120
Study 30063488 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy intervention
Number of subjects: 1443
Study 30063488 — intervention group
Group type: COMPARATOR
Intervention: Normal clinical practice (control)
Number of subjects: 1443
Study 27875542 — intervention group
Group type: EXPERIMENTAL
Intervention: PC101 management tool training and expanded prescribing authority for nurses
Number of subjects: 4393
Study 24583632 — intervention group
Group type: EXPERIMENTAL
Intervention: WEBCARE intervention
Number of subjects: 146
Study 24583632 — intervention group
Group type: COMPARATOR
Intervention: Usual Care group
Number of subjects: 146
Study 24011464 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy on one side of the jaw
Number of subjects: 10
Study 24011464 — intervention group
Group type: COMPARATOR
Intervention: Non-treated side (control)
Number of subjects: 10
Study 22950883 — intervention group
Group type: EXPERIMENTAL
Intervention: SC counselling arm (363 participants)
Number of subjects: 1100
Study 22950883 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + PA counselling arm (366 participants)
Number of subjects: 1100
Study 22950883 — intervention group
Group type: COMPARATOR
Intervention: Control group (371 participants)
Number of subjects: 1100
Study 19956085 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg DMXB-A
Number of subjects: 16
Study 19956085 — intervention group
Group type: COMPARATOR
Intervention: 75 mg DMXB-A
Number of subjects: 16
Study 19956085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17335057 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Ljungan virus (LV) in brain tissue
Number of subjects: 10
Study 17335057 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of Ljungan virus (LV) in placenta
Number of subjects: 10
Study 15895328 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-centered treatment (FCT) (4h/d, 6d/wk, for 3 wk)
Number of subjects: 174
Study 15895328 — intervention group
Group type: COMPARATOR
Intervention: Pain-centered treatment (PCT) (2.5h/d, 6d/wk, for 3 wk)
Number of subjects: 174
Study 12126662 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus femoris transfer surgery
Number of subjects: 16
Study 12126662 — intervention group
Group type: COMPARATOR
Intervention: Unimpaired control subjects
Number of subjects: 16
Study 10443771 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g)
Number of subjects: 0
Study 10443771 — intervention group
Group type: COMPARATOR
Intervention: Saccharin (50 mg)
Number of subjects: 0
Study 8675378 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape of information focusing on expected physical symptoms and their management in addition to usual care
Number of subjects: 82
Study 8675378 — intervention group
Group type: COMPARATOR
Intervention: Usual cardiac discharge information protocol
Number of subjects: 82
Study 1611017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystokinin octapeptide (CCK‐8, 0.06 microgram/kg)
Number of subjects: 4
Study 1611017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 6391504 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (25 mg per kg of body weight, 3 times daily for one or two days)
Number of subjects: 67
Study 6391504 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (two-day dosage schedule)
Number of subjects: 67
Study 6391504 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (one-day dosage schedule)
Number of subjects: 67
Study 6391504 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (both dosages)
Number of subjects: 67
Study 31775808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-substance injection with Diprospan (1 cc) and 1% xylocaine (1 cc)
Number of subjects: 24
Study 31775808 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 cc) and 1% xylocaine (1 cc)
Number of subjects: 24
Study 30572588 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 5% energy from saturated fatty acids (SFA) with monounsaturated fatty acids (MUFA)
Number of subjects: 6942
Study 30572588 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 5% energy from saturated fatty acids (SFA) with polyunsaturated fatty acids (PUFA)
Number of subjects: 6942
Study 30572588 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing proteins with MUFA or PUFA
Number of subjects: 6942
Study 30572588 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily substitution of one portion of red meat with white meat, oily fish or white fish
Number of subjects: 6942
Study 30572588 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing intake of unsaturated fatty acids at the expense of SFA, proteins, and carbohydrates
Number of subjects: 6942
Study 27349575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IBS and positive anti‐tTG results (Group II, 8 patients)
Number of subjects: 100
Study 27349575 — intervention group
Group type: COMPARATOR
Intervention: Patients with IBS and negative anti‐tTG results (Group I, 92 patients)
Number of subjects: 100
Study 27349575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with IBS and positive anti‐tTG results (Group II)
Number of subjects: 100
Study 27349575 — intervention group
Group type: COMPARATOR
Intervention: Patients with IBS and negative anti‐tTG results (Group I)
Number of subjects: 100
Study 24794879 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 485
Study 24794879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 485
Study 22791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-cyproterone acetate (EE-CA)
Number of subjects: 34
Study 22791755 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone (7.5 mg/d), flutamide (62.5 mg/d), and metformin (850 mg/d) (PioFluMet)
Number of subjects: 34
Study 20004655 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow eating pace
Number of subjects: 24
Study 20004655 — intervention group
Group type: COMPARATOR
Intervention: Normal eating pace
Number of subjects: 24
Study 16954331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous microdialysis of N(G)-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor) during local warming to 42 degrees C
Number of subjects: 0
Study 16954331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) for assessment of maximum cutaneous vascular conductance (CVC)
Number of subjects: 0
Study 16954331 — intervention group
Group type: EXPERIMENTAL
Intervention: Local warming to 42 degrees C
Number of subjects: 0
Study 15848573 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 260
Study 15848573 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 260
Study 11914932 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg NSC‐631570
Number of subjects: 90
Study 11914932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg gemcitabine/m2 followed by 20 mg NSC‐631570 weekly
Number of subjects: 90
Study 11914932 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg gemcitabine/m2
Number of subjects: 90
Study 10382476 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-managed care
Number of subjects: 1299
Study 10382476 — intervention group
Group type: COMPARATOR
Intervention: Shared care
Number of subjects: 1299
Study 7617115 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diets
Number of subjects: 17
Study 7617115 — intervention group
Group type: COMPARATOR
Intervention: Captopril treatment
Number of subjects: 17
Study 1320917 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral granisetron 1.0 mg twice daily
Number of subjects: 930
Study 1320917 — intervention group
Group type: COMPARATOR
Intervention: Oral granisetron 0.25 mg twice daily
Number of subjects: 930
Study 1320917 — intervention group
Group type: COMPARATOR
Intervention: Oral granisetron 0.5 mg twice daily
Number of subjects: 930
Study 1320917 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (constipation, headache, abdominal pain, fever, leucopenia, asthenia)
Number of subjects: 930
Study 6824435 — intervention group
Group type: EXPERIMENTAL
Intervention: AM clipper method
Number of subjects: 1013
Study 6824435 — intervention group
Group type: COMPARATOR
Intervention: Shaving
Number of subjects: 1013
Study 31470240 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG+OB (18 ng/ml nicotine)
Number of subjects: 60
Study 31470240 — intervention group
Group type: COMPARATOR
Intervention: OB-only
Number of subjects: 60
Study 31470240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29756979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (10 g every 8 hours)
Number of subjects: 262
Study 29756979 — intervention group
Group type: COMPARATOR
Intervention: Control (no glutamine)
Number of subjects: 262
Study 25091553 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion with standard treatment
Number of subjects: 48
Study 25091553 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 48
Study 24125895 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-G
Number of subjects: 162
Study 24125895 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ-C30
Number of subjects: 162
Study 22553251 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammaretroviral vector-engineered T cells (CD4ζ)
Number of subjects: 500
Study 19560110 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 0
Study 19560110 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 0
Study 19560110 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 17623016 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin plus statin (10 mg of rosuvastatin)
Number of subjects: 55
Study 17623016 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin plus placebo
Number of subjects: 55
Study 15793417 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibulo-ocular reflex gaze stabilization exercises (started 3 days after surgery)
Number of subjects: 65
Study 15793417 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance physiotherapy
Number of subjects: 65
Study 15793417 — intervention group
Group type: COMPARATOR
Intervention: Control group (27 patients)
Number of subjects: 65
Study 15259388 — intervention group
Group type: EXPERIMENTAL
Intervention: No-delay prosaccade condition
Number of subjects: 0
Study 15259388 — intervention group
Group type: EXPERIMENTAL
Intervention: No-delay antisaccade condition
Number of subjects: 0
Study 15259388 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay tasks
Number of subjects: 0
Study 15259388 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial working memory task
Number of subjects: 0
Study 9856707 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) analgesia
Number of subjects: 1223
Study 9856707 — intervention group
Group type: COMPARATOR
Intervention: Intravenous meperidine
Number of subjects: 1223
Study 7789138 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of Cardiac Operative Risk (RCOR) Trial
Number of subjects: 0
Study 2695875 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I brachytherapy
Number of subjects: 0
Study 2695875 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium ion irradiation
Number of subjects: 0
Study 2695875 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 0
Study 1107604 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and cyclophosphamide
Number of subjects: 33
Study 1107604 — intervention group
Group type: COMPARATOR
Intervention: adriamycin and cyclophosphamide
Number of subjects: 33
Study 30715451 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a BCG scar
Number of subjects: 2213
Study 30715451 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a BCG scar whose mothers also had a BCG scar
Number of subjects: 2213
Study 30715451 — intervention group
Group type: COMPARATOR
Intervention: Children with no BCG scar whose mothers had no BCG scar
Number of subjects: 2213
Study 31332700 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEDP-guided hydration
Number of subjects: 114
Study 31332700 — intervention group
Group type: COMPARATOR
Intervention: Standard hydration
Number of subjects: 114
Study 28545545 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ethnography observations and staff interviews
Number of subjects: 0
Study 26060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 50
Study 26060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauzes
Number of subjects: 50
Study 26060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing Gel
Number of subjects: 50
Study 26060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel
Number of subjects: 50
Study 26060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam
Number of subjects: 50
Study 26060395 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Symptoms Score
Number of subjects: 50
Study 23589390 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based assessment of cognitive function
Number of subjects: 1635
Study 23589390 — intervention group
Group type: COMPARATOR
Intervention: Older participants
Number of subjects: 1635
Study 23589390 — intervention group
Group type: COMPARATOR
Intervention: Participants with no current computer use
Number of subjects: 1635
Study 21534446 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal ulcer patients
Number of subjects: 175
Study 21534446 — intervention group
Group type: COMPARATOR
Intervention: Gastric ulcer patients
Number of subjects: 175
Study 20077879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasmakinetics vessel sealing
Number of subjects: 94
Study 20077879 — intervention group
Group type: COMPARATOR
Intervention: Standard suture technique
Number of subjects: 94
Study 16719128 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion baths
Number of subjects: 108
Study 16719128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immersion baths)
Number of subjects: 108
Study 15122540 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (150 mg mean daily dose)
Number of subjects: 62
Study 15122540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 11322842 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage
Number of subjects: 262
Study 11322842 — intervention group
Group type: COMPARATOR
Intervention: Self-care education
Number of subjects: 262
Study 11322842 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese Medical acupuncture
Number of subjects: 262
Study 9269062 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at 0 and 24 weeks (25 U of viral antigen)
Number of subjects: 100
Study 9269062 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose at 24 weeks
Number of subjects: 100
Study 8323214 — intervention group
Group type: EXPERIMENTAL
Intervention: Wiping skin dry after 30 seconds of application of aqueous povidone-iodine
Number of subjects: 24
Study 8323214 — intervention group
Group type: COMPARATOR
Intervention: Leaving the aqueous povidone-iodine to dry
Number of subjects: 24
Study 3087091 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (3 X 0.02 mg/d)
Number of subjects: 109
Study 3087091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 30526610 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial diversity in the respiratory tract
Number of subjects: 34
Study 27418378 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 80
Study 27418378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24158846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral bevacizumab (1.25 mg, 50 µL)
Number of subjects: 138
Study 24158846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced salt solution, 50 µL)
Number of subjects: 138
Study 23107655 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3PUFA (1 g/day)
Number of subjects: 388
Study 23107655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 19593146 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group VIMA)
Number of subjects: 26
Study 19593146 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA) with remifentanil and propofol (group TIVA)
Number of subjects: 26
Study 18853563 — intervention group
Group type: EXPERIMENTAL
Intervention: Synaesthetic AV animations
Number of subjects: 0
Study 18853563 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (rotated clips, color changed clips, random AV pairings, animated clips generated by non-synaesthetes)
Number of subjects: 0
Study 16192839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (AMSP)
Number of subjects: 40
Study 16192839 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (QTP)
Number of subjects: 40
Study 12625607 — intervention group
Group type: EXPERIMENTAL
Intervention: CS -> SVC+Can
Number of subjects: 18
Study 12625607 — intervention group
Group type: COMPARATOR
Intervention: RV -> SVC+Can
Number of subjects: 18
Study 12625607 — intervention group
Group type: COMPARATOR
Intervention: RV+CS -> SVC+Can
Number of subjects: 18
Study 10476941 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 IU/kg recombinant human interferon-alpha (rHuIFN-alpha)
Number of subjects: 57
Study 10476941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 8759066 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apo B concentrations measured at entry
Number of subjects: 2155
Study 8759066 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apo A-I concentrations measured at entry
Number of subjects: 2155
Study 8759066 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo B as a metabolic variable
Number of subjects: 2155
Study 1890744 — intervention group
Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (II) regimen (HLBI 3 x 10(6) units/day, twice a week)
Number of subjects: 16
Study 1890744 — intervention group
Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (I) regimen (HLBI 3 x 10(6) units/day, daily, 56 days)
Number of subjects: 16
Study 1890744 — intervention group
Group type: COMPARATOR
Intervention: VCAP regimen only
Number of subjects: 16
Study 1890744 — intervention group
Group type: COMPARATOR
Intervention: Control group (VCAP)
Number of subjects: 16
Study 1890744 — intervention group
Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (I) group
Number of subjects: 16
Study 1890744 — intervention group
Group type: EXPERIMENTAL
Intervention: HLBI-VCAP (II) group
Number of subjects: 16
Study 6356767 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (AC)
Number of subjects: 238
Study 6356767 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 238
Study 31839177 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 0
Study 30481149 — intervention group
Group type: EXPERIMENTAL
Intervention: Orderly displayed ECGs of limb leads
Number of subjects: 147
Study 30481149 — intervention group
Group type: COMPARATOR
Intervention: Classically displayed ECGs of limb leads
Number of subjects: 147
Study 27434611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency treadmill training (2 times a week)
Number of subjects: 30
Study 27434611 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-frequency treadmill training (3 times a week)
Number of subjects: 30
Study 27434611 — intervention group
Group type: COMPARATOR
Intervention: High-frequency treadmill training (5 times a week)
Number of subjects: 30
Study 25529384 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction cisplatin and capecitabine (PX)
Number of subjects: 706
Study 25529384 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction PX
Number of subjects: 706
Study 25529384 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 706
Study 25529384 — intervention group
Group type: COMPARATOR
Intervention: Induction PF
Number of subjects: 706
Study 25529384 — intervention group
Group type: COMPARATOR
Intervention: Induction sequences
Number of subjects: 706
Study 25529384 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant PF
Number of subjects: 706
Study 25001306 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine-artesunate
Number of subjects: 684